Zhitong Finance App News, Osecon (002755.SZ) issued an announcement. Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for malibavir tablets approved and issued by the State Drug Administration. The drug is classified as a chemical drug in 4 categories. Obtaining the “Drug Registration Certificate” this time is regarded as passing the consistency evaluation, which will further expand the company's pipeline in the field of anti-infection and enhance the company's competitiveness in this field.

According to reports, malibavir is the only anti-cytomegalovirus (CMV) marketed drug in the world that targets pUL97 protein kinase. It is also the world's first and only approved treatment for refractor/drug-resistant cytomegalovirus infection/disease in pediatric patients after transplantation. It is used to treat one or more previous treatments (ganciclovir, valganciclovir, cidofovir, or sodium phosphonate) in adults and children (12 years and over, with or without genotype resistance) after transplantation of solid CMV transplantation infections and/or diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.